About
Michael Tomsicek has served on Acrivon's Board since October 2022 and chairs its Audit Committee. He has served on the board of Milestone Pharmaceuticals USA since April 2019. He was Chief Financial Officer of CRISPR Therapeutics AG from November 2017 to October 2021 and Chief Financial Officer of Abiomed from July 2015 to August 2017. Mr. Tomsicek holds an M.B.A. and a B.S. in engineering, both from the University of Wisconsin.
Roles
Acrivon Therapeutics, Inc.
Director · Current role
October 2022–present
CRISPR Therapeutics AG
Chief Financial Officer
2017 - 2021
Abiomed, Inc.
Chief Financial Officer
2015 - 2017
External Roles
Milestone Pharmaceuticals USA, Inc.
Director
2019 - present
Director Compensation
FY 2025Fees earned or paid in cash
$55,000
ComponentAnnual cash retainers and committee/leadership fees earned in 2025
Option awards
$17,870
ComponentStock options granted during 2025, ASC 718 grant-date fair value
Total
$72,870
Also at Acrivon Therapeutics, Inc.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.